MedTrace Logo

Epidermal Cell Transplantation in Vitiligo Skin With and Without Narrow-band Ultraviolet B (UVB) Treatment

NCT00615355 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2017-01-12

No results posted yet for this study

Summary

The effect of treatment with narrow-band UVB 311 nm after transplantation of harvested autologous epidermal cells on vitiligo lesions will be investigated.

Conditions

  • Vitiligo

Interventions

RADIATION

UVB 311 nm radiation

UVB 311 nm radiation randomized to one half of the transplanted vitiligo lesion given 2 times a week for 3 months; the other half of the transplanted lesion remains UV-non-irradiated

DEVICE

UVB 311nm

Repeated UVB 311nm narrowband irradiation (24 exposures)

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Angelika Hofer · Medical Univsersity of Graz, Department of Dermatology, Austria

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00615355 on ClinicalTrials.gov